Boundless Bio (Boundless Bio) ROCE % : -59.51% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Boundless Bio's annualized ROCE % for the quarter that ended in Mar. 2024 was -59.51%.

Boundless Bio ROCE % Historical Data

The historical data trend for Boundless Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio ROCE % Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-23.03

-51.93

-57.79

Boundless Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial				-69.97	-38.04	-42.70	-43.47	-59.51

Boundless Bio ROCE % Calculation

Boundless Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-54.796	/	( ( (76.829 - 7.728)	+	(129.894 - 9.359) )	/ 2 )
	=	-54.796	/	( (69.101	+	120.535)	/ 2 )
	=	-54.796	/	94.818
	=	-57.79 %

Boundless Bio's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-67.532	/	( ( (129.894 - 9.359)	+	(117.077 - 10.644) )	/ 2 )
	=	-67.532	/	( ( 120.535	+	106.433 )	/ 2 )
	=	-67.532	/	113.484
	=	-59.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Boundless Bio (NAS:BOLD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Boundless Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Boundless Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio (Boundless Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus

Boundless Bio Announces Pricing of Initial Public Offering

By Business Wire • 03-27-2024